Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Angiogenesis. 2019 Jan 14;22(3):369–382. doi: 10.1007/s10456-019-09662-4

Fig. 4.

Fig. 4.

Anti-Scg3 mAb has minimal adverse effects on retinal function after intravitreal injection. Anti-Scg3 mAb or aflibercept (4 μg/eye) was intravitreally injected into mice at P14 with PBS for the fellow eye. ERG was performed at P21 (not shown) and P42. a Representative ERG of aflibercept-treated eye at P42. b Representative ERG of anti-Scg3 mAb-treated eye at P42. c Amplitude of a-wave at P42. d Latency of a-wave at P42. e Amplitude of b-wave at P42. f Latency of b-wave at P42. ± SEM, n=6 mice, paired t-test.